Zydus Cadila to commence phase II clinical trials of Covid-19 vaccine from August 6

Credit: IndiaTimes- Published on August 5, 2020

Video credit: Newsflare
Published on August 3, 2020 -  03:00
Russia hopes to register a vaccine against COVID-19 within 10 days
The Russian Direct Investment Funds hopes to find one of the vaccines against COVID-19, to be developed in Russia, and to be registered within 10 days, according to the head of the fund, Kirill Dmítriyev. They assured that it will soon have the capacity to produce hundreds and thousands each month. They will raise its production of the new COVID-19 vaccine to "several million" at the beginning of next year. After the completion of the clinical tests of the new drug, the Gamaleya Institute has announced the start of the procedures for its registration. "In that case, we will overtake all the other countries, including the United States," said the head of the sovereign wealth fund, Dmítriyev, in an interview on the Rossiya 24 channel. According to the official, the production volume of this new vaccine could reach 10 million per month by the end of this year. Russian Commerce Minister, Denis Maturov, assured the state agency TASS that "according to the first estimates ... we will be able to provide several hundred thousand doses of the vaccine every month starting this year, and then several million from the beginning next year". Maturov explained that three biomedical companies will begin, in September, the industrial production of the vaccine developed by the research laboratory in epidemiology and microbiology, Nikolái Gamaleia. The Minister of Health of Russia, Mikhail Murashko, confirmed last Saturday that the phase of clinical trials of the vaccine prepared by the National Research Center for Epidemiology and Microbiology Gamaleya in conjunction with the Russian Ministry of Defense, had been completed and that it was preparing the package of documents necessary to register the medication. Once the registration certificate is obtained, the vaccine will begin to be supplied among the country's population, first among the members of special groups such as doctors and teachers, while a mass vaccination is scheduled for October, the minister said. The Defense Ministry noted that the results of the trials unequivocally showed the development of an immune response in all volunteers, with no side effects, complications, or unwanted reactions.

You are here

💡 newsR Knowledge: Other News Mentions

Coronavirus disease 2019

Infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2
Eminent nuclear scientist Sekhar Basu died of Covid-19 in a Kolkata hospital early Thursday, bringing the curtain down on a career that saw him championing major..
Credit: IndiaTimes - Published 3 hours ago

The seven-day rolling average growth rate in active cases of Covid-19 in India has slipped into the negative helped by recoveries exceeding daily new cases for..
Credit: IndiaTimes - Published 3 hours ago

Credit: IndiaTimes - Published 7 hours ago

Hospital sources also said his blood platelet count was also dropping. Earlier in the evening, Sisodia was put on oxygen support, and remained under constant..
Credit: DNA - Published 8 hours ago

Related videos from verified sources

Serum Institute will start phase-III trials after clearances: ICMR on COVID vaccine 01:21
Credit: ANI - Published 1 week ago 

Covid: Serum Institute begins human trials, 5 volunteers given first shot 02:01
Credit: HT Digital Content - Published on August 26, 2020 

Covid update: India vaccine progress; another minister infected; IMF on economy 02:41
Credit: HT Digital Content - Published on August 4, 2020 

Related news from verified sources

Drug firm Zydus Cadila on Wednesday announced that its plasmid DNA vaccine to prevent *COVID-19* -- ZyCoV-D -- was found to be safe and well-tolerated in phase I...
on August 5, 2020 • Mid-Day

You might like